1. Patient
Diagnosis
Mutant droplets dected in tumour
Assays
Mutant droplets dected in plasma
Assay
Genetic profiling by targeted hybrid capture + NGS
QC2-02
Unknown
Yes* (EZH2 Y641N)
Uniplex/Duplex/Inverted (EZH2); EZH2/STAT6 Inv.; Multiplex EZH2
Not tested
EZH2 Y641N
QC2-03
Tly
Yes (CCND3 I290R)
MYD88/CCND3 Duplex
CCND3 I290R
QC2-04
GCB-DLBCL
Yes (STAT6 D419G)
Multiplex STAT6;EZH2/STAT6 Inv.
Uniplex STAT6 D419G / day0
STAT6 D419G
QC2-05 No
QC2-06
non-GCB-DLBCL
No*
EZH2/STAT6 Inv.
QC2-07
Yes (EZH2 Y641H)
Multiplex EZH2; EZH2/STAT6 Inv.
Uniplex EZH2 Y641H / day0 / day15
EZH2 Y641H
QC2-08
Yes* (STAT6 D419G)
Multiplex EZH2; Multiplex STAT6; EZH2/STAT6 Inv.
QC2-11
Multiplex EZH2;EZH2/STAT6 Inv.
QC2-12
Yes (STAT6 D419A)
MYD88/CCND3 Duplex; Multiplex STAT6; EZH2/STAT6 Inv.
Uniplex STAT6 D419A / day0 / day15
STAT6 D419A
QC2-13
ABC-DLBCL
MYD88/CCND3 Duplex; Multiplex EZH2; EZH2/STAT6 Inv.
QC2-15
Yes (EZH2 Y641S; STAT6 D419G)
Multiplex EZH2; Multiplex STAT6EZH2/STAT6 Inv.
Uniplex EZH2 Y641S; Uniplex STAT6 D419G / day0 / day15
EZH2 Y641S; STAT6 D419G
QC2-17
Uniplex EZH2 Y641H / day0
QC2-19
MYD88/CCND3 Duplex;Multiplex STAT6;EZH2/STAT6 Inv.
QC2-20
Yes (STAT6 D419N; CCND3 I290R)
Yes (STAT6 D419N)
Uniplex STAT6 D419N / day0 / day15
STAT6 D419N
QC2-21
MYD88/CCND3 Duplex;EZH2/STAT6 Inv.
QC2-23
Yes (MYD88 L265P)
MYD88 L265P
QC2-24
QC2-25
MYD88/CCND3 Duplex; Multiplex EZH2
QC2-26
MYD88/CCND3 Duplex; Multiplex STAT6
QC2-29
QC2-30
QC2-32
Yes (EZH2 Y641S)
Uniplex EZH2 Y641S;EZH2/STAT6 Inv.
Uniplex EZH2 Y641S / day0 / day15
EZH2 Y641S
QC2-33
MYD88/CCND3 Duplex; EZH2/STAT6 Inv.
QC2-34
Yes (EZH2 Y641N; STAT6 D419N)
Plasma not available
EZH2 Y641N; STAT6 D419N
QC2-35
Yes (STAT6 D419H)
Multiplex STAT6
Uniplex STAT6 D419H / day0 / day 15
STAT6 D419H
QC2-36 `
QC2-39
QC2-40
QC2-42
BC002
DLBCL
Yes (EZH2 Y641N)
Uniplex EZH2 Y641N
Pt022
Uniplex STAT6 D419G
ctDNA undetected
Pt808
Multiplex STAT6; EZH2/STAT6 Inv.
IROL-91
LPL
Uniplex MYD88 L265P
IROL-101
Supplemental Data Table 1. Summary of the clinical samples used in the present study, including fresh tumor, FFPE (indicated by asterisks in the third column) and liquid biopsies.
The different array of assays tested in each sample as well as whether mutant DNA was detected or not is also indicated. Tly: transformed follicular lymphoma; GCB-DLBCL: germinal center B-cell-like diffuse large B-Cell lymphoma; ABC-DLBCL: activated B-cell-like diffuse large B-Cell lymphoma; non-GBC DLBCL: Non-germinal center B-cell-like diffuse large B-Cell lymphoma. More information about the clinical samples starting with QC2 can be found in references 13 and 34.